Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16838736 | 1.00 | CYP1A2 (0.38) | CYP1A2SMN1; SMN2ALDH1A1USP2LMNA | |
| Hydrochloric Acid SCHEMBL5616975 | 0.98 | CYP1A2 (0.37) | CYP1A2SMN1; SMN2ALDH1A1USP2LMNA | |
| SCHEMBL2079 | 0.98 | CYP1A2 (0.39) | CYP1A2SMN1; SMN2ALDH1A1USP2LMNA | |
| SCHEMBL425037 | 0.94 | SMN1; SMN2 (0.41) | CYP1A2SMN1; SMN2ALDH1A1LMNAALOX15 | |
| Hydrochloric Acid SCHEMBL5616928 | 0.92 | SMN1; SMN2 (0.41) | CYP1A2SMN1; SMN2ALDH1A1ALOX15POLB | |
| SCHEMBL1161503 | 0.90 | CYP1A2 (0.42) | CYP1A2SMN1; SMN2ALDH1A1LMNAALOX15 | |
| Hydrochloric Acid SCHEMBL1141219 | 0.88 | CYP1A2 (0.41) | CYP1A2SMN1; SMN2ALDH1A1LMNAALOX15 | |
| SCHEMBL19415396 | 0.85 | TSHR (0.37) | CYP1A2SMN1; SMN2ALDH1A1USP2LMNA | |
| SCHEMBL1142569 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL2185965 | 0.82 | CYP4F2 (0.40) | SMN1; SMN2ALDH1A1POLBKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448493-A1 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240327376-A1 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2023111985-A1 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230069963-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-09 | — | — | US | disclosed |
| EP-3903788-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020138015-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | 大正製薬株式会社 | 2020-07-02 | — | — | WO | disclosed |
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5955487-A | TREATING HIGH BLOOD PRESSURE, CARDIAC INSUFFICIENCY, GLAUCOMA | CIBA-GEIGY CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| US-5929067-A | N-ACYLATING AMINE DERIVATIVE OF CAPROLACTAM COMPOUND WITH A CARBOXYLIC ACID OR DERIVATIVES TO FORM AMIDE DERIVATIVE OF CAPROLACTAM COMPOUND | NOVARTIS AG (CH) | 1999-07-27 | — | — | US | disclosed |
| EP-0810991-B1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | NOVARTIS AG (CH) | 1999-04-14 | — | — | EP | disclosed |
| CN-1175944-A | 1 -aryl -2 -acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists | CIBA GEIGY AG (CH) | 1998-03-11 | — | — | CN | disclosed |
| US-5620998-A | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| US-5506240-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | CYP1A2 166/4885SMN1; SMN2 2832/4885ALDH1A1 2293/4885 |
| US-20240327376-A1 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | EGLN2, EGLN3, HIF1AN | CYP1A2 1376/4885SMN1; SMN2 2564/4885ALDH1A1 663/4885 |
| US-20230069963-A1 | PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | ZC3HAV1, ZC3HAV1L, IL5 | CYP1A2 3522/4885SMN1; SMN2 761/4885ALDH1A1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.